

UPM activities with nuclear data (ND) in other applications

Gonzalo F. Garcia-Fernandez¹, Eduardo Gallego¹, Jose M. Gomez-Ros²
(gf.garcia@upm.com)

Main contributors in specific areas of the project

Alejandro Carabe-Fernandez³, Alejandro Bertolet-Reina⁴, Roberto Méndez², Ana M^a Romero², Hector R. Vega-Carrillo⁵

Karen A. Guzman-Garcia⁵, Lenin E. Cevallo-Robalino⁶

Alfredo Lorente Fillol¹, Sviatoslav Ibáñez¹, Roberto García-Baonza¹, Sergio Rivera², Pablo Gracia Tolosana¹, Adrián Murcia Morales¹

**Hybrid Meeting (virtual & in-person) on
“Nuclear Databases for Nuclear Reactor Applications
within the Spanish Nuclear Sector”**

September 20 (Tuesday), 2022. 09:00-13:00h

UPM activities with nuclear data (ND) in other applications

Scope

Purpose and context






Research activities with ND, *the film*

**Health facilities (PT)
(The ten recommendations)**

Summary





Other activities with Nuclear Data at UPM



Health
Facilities



Proton therapy facilities






REDUCCIÓN EFECTOS A LARGO PLAZO EN PACIENTES INFANTILES (<10 años)

Reducción de 1,5 a 6 veces de los efectos secundarios frecuentes (>19 % de incidencia) inducidos por la radiación

Outcome	Modality	Events	Reduction	P-value
Hypothyroidism	Protons	23%	2.8	<0.001
	X-rays	65%		
Sex hormone deficiency	Protons	3%	6.3	0.025
	X-rays	19%		
Endocrine replacement therapy	Protons	55%	1.4	0.030
	X-rays	78%		


Eaton et al, Neuro. Oncol. 2016 18: 881-7



Robert Wilson

The advent of Protontherapy in Spain

Number	Rooms	Footprint (Aprox)	Operation
1	1	360 m ²	Dec 2019
	1+(1)	800 m ²	March 2020



(AM from PTCOG 2020 w/Spain Projected to 12 centers)

Order	Country	Centers/10Mh	Country	Rooms/10Mh
1	Spain	2,6	Denmark	6,7
2	The Netherlands	1,8	Switzerland	5,7
3	Denmark	1,7	Czech Republic	3,6
4	Japan	1,4	The Netherlands	3,5
5	Switzerland	1,4	Austria	3,3
6	USA	1,1	Taiwan	3,3
7	Austria	1,1	USA	3,3
8	Sweden	1,0	Spain	2,6
9	Czech Republic	0,9	Japan	2,5
10	Belgium	0,8	Sweden	2,0
11	Taiwan	0,8	Germany	2,0
12	England	0,7	England	1,5
13	Germany	0,7	Italy	1,3
14	Italy	0,5	South Korea	1,3
15	France	0,5	France	1,3
16	South Korea			
17	Russia			
18	Poland			
19	China			
20	India			

Gantry Rotation	
	220°
	360°

Importe (IVA exc.)	Importe (IVA inc.)
22.400.000,00 €	





To infinity and beyond


2018→0 2020→ 2 (private) + 1 Santander 2025?→ 13 (+10 public)

Research Project

Contributions to the operational radiation protection in compact proton therapy centers (CPTC)









Reduce Footprint



Physics, Nuclear Data and Nuclear Models in PT

Proton interactions → Neutron Fields
 Neutron interactions → Impact in facility




Neutron yielding and neutron transport



The proton therapy beamline



ESTIMATED PROTON NUMBER [nA.h]



Main Interaction

Component	En
Cyclotron	
Degrader	
Collimator	
Divergence Slits	
Momentum Slit	
Patient	70 - 230 Tissue

Energy (MeV)	70	85	115	160	200	230
Efficiency (%)	0,2	0,3	0,8	1,8	5	12





RP in proton centers: Starting Point

Workload (nA-h/year) → Estimation of Proton fields (annual dose) → Beam losses

COMPLEX INPUT: Number of patients x Number of Fields x Time per field x Current x Working days x (1h/60 min)

- Factor
- Regulation
- Occupancy
- Types
- Dose limits
- Conservative

Modality	% of total workload	Working Protons per week	Beam current (nA)	Average dose (Gy)	Total dose (Gy)	Average dose rate (Gy/h)	Average dose rate (Gy/min)
Proton Therapy	95	37.5	25	2.4	90	3.6	0.06
Proton Research	5	1.875	1.25	0.12	4.5	0.18	0.003
Proton Beam Losses	0	0	0	0	0	0	0



, 2 Gy/patient

)
gain)

ly: 10

3

ance

as, facility

t Dose Equivalent, H*(10) (Hp*(10))

ties (conservatives, 20y)





Components (patients), interactions – **Workload → Delivery mode**



Neutron yielding and neutron transport

Nuclear Data and Physical Model

Particle type ^a (Intranuclear Cascade)	Energy [GeV]	
	0.8	0.94
Nucleons (neutron, proton)	1 [†]	Bertini
	2	ISABEL
	3	INCL4 [‡]
	4	CEM03 [§]
Light ions (deuteron, triton, ³ H, alpha)	1 [†]	ISABEL
	2	LAO
Heavy ions (A > 4)		LAO



Verification of barriers and shielding against neutron and gamma radiation

Neutron Libraries for MCNP



- The MCNP6 data libraries are contained in the MCNP6 RSICC package.

Continuous-energy neutron libraries for MCNP6:

- endf71x¹⁾ ENDF/B-VII.1
- endf70 a-k ENDF/B-VII.0

Older libraries, retained for historical reasons:


- t16_2003 preliminary ENDF/B-VII, for a few isotopes
- acti ENDF/B-VI.8
- endR60 ENDF/B-VI.6
- endR60 ENDF/B-VI.2
- endR62mt A multi-temperature Neutron Data Library
- ures ENDF/B-VI Neutron Library with Probability Tables
- endf6dn ENDF/B-VI Neutron Library with Delayed Neutron Tables
- newxs LANL based evaluations
- rmccs ENDF/B-V and LANL based evaluations
- rmccsa ENDF/B-V and LANL
- endf5p ENDF/B-V based
- endf5u ENDF/B-V based
- misc5xs Contains a number of previously released smaller libraries
- kidman Fission product evaluations
- 100xs LANL based
- end192 1992 ENDL library from LLNL
- end185 1985 ENDL library
- endf5mt Multi-temperature data previously released as eprxs and u600k



UNCLASSIFIED

Operated by Los Alamos National Security, LLC for the U.S. Department of Energy's NNSA

B - 05 - 13



INC Model Options in MCNP6



Variable	Bertini	ISABEL	CEM (default)	INCL	LAQGSM
Lower Energy	20-150 MeV	20-150 MeV	~ 10 MeV	~ 100 MeV (not in MCNP: ~ 5 MeV/A)	~ 100 MeV/A (not in MCNP: ~ a few MeV/A)
Upper Energy	3.5 GeV (nuc-nuc) 2.5 GeV (pion-nuc)	1 GeV	5 GeV	2 GeV (not in MCNP: ~ 15 GeV)	~ 1 TeV/A (not in MCNP: ~ 20-100 TeV)
Target Nuclei	All	All	A ≥ 4	All	All
Incident particles	h, n, pions	h, n, \bar{h} , \bar{n} (not in MCNP: also A=4)	h, n, pions, γ	h, n, A ≤ 4 (not in MCNP: ~ A<16)	Almost all particles & ions




UNCLASSIFIED

Operated by Los Alamos National Security, LLC for the U.S. Department of Energy's NNSA






B - 10 - 31

Physical Processes included in PHITS



- | | | |
|-----------------------------|--|---|
| Collision & decay processes | Nuclear interaction | <ul style="list-style-type: none"> High-energy spallation reaction Photon and muon-induced reaction Absorption, resonance, fission reaction |
| | Atomic interaction | <ul style="list-style-type: none"> Photo-electric, Compton, pair production Møller/Bhabha scattering, Annihilation Bremsstrahlung Knock-out electron (δ-ray) production Ionization/excitation (track structure mode) |
| | Particle decay | <ul style="list-style-type: none"> Decay with lifetime (neutron, μ, π etc.) |
| Transport process | <ul style="list-style-type: none"> Ionization / excitation External field / reflection | <ul style="list-style-type: none"> Continuous slowing down approximation Energy & angular straggling Electric / magnetic field Gravity Reflection (super mirror etc.) |



Verification of barriers and shielding against neutron and gamma radiation



Máx.: 0.455 mSv/year

12-15% lower

Isodose plots





Verification of barriers and shielding against neutron and gamma radiation

Checking the shielding of compact centers



MC methods

Thickness proposed by vendors



Both facilities always below international legal limits (1 mSv, general public)

Synchrocyclotron
One treatment room
360 m² footprint
2.8 m thickness in main barriers




Synchrotron
One treatment room
expandable
800 m² footprint
2 m thickness in main barriers

Intercomparing
CPTC:
synchrocyclotron
vs. synchrotron


Expansion to new types of centers planned for the Public System

Study of different materials in barriers


Attenuation plots with different types of concrete





Attenuation is essential but not enough



Comparative of several materials (concretes)



Different materials in different places and mix barriers



Compromise between attenuation, activation in components, and cost of building

Impact of radiation on environment inside and around CPTC

Air activation

Neutron capture in ^{40}Ar : $^{40}\text{Ar}(n,\gamma)^{41}\text{Ar}$ (Cross section ^{40}Ar , $\sigma = 610$ mb)

Spallation processes on ^{14}N and ^{16}O atoms, with neutrons above 20 MeV of energy

Air renewal rate, r ($r > 6$ RPH, $\lambda_{\text{effective}} = \lambda + r$), underpressure, treatment and humidity

Water activation + ground activation in soil

Spallation processes on O atoms, with neutrons above 20 MeV of energy

Productions of same radionuclides as air, except ^{41}Ar :

Long-lived isotopes: ^3H and ^7Be

Short-lived isotopes: ^{11}C , ^{13}N , ^{15}O , ^{14}O , ^{18}F

Spallation processes with high energy neutrons ($E_n > 20$ MeV) in Oxygene (^{16}O)				
Target	Reaction	Cross section (mb)	Nuclide yielded	Half-life
^{16}O	$^{16}\text{O}(n,x)^3\text{H}$	30	^3H	12.3 y
^{16}O	$^{16}\text{O}(n,x)^7\text{Be}$	5	^7Be	53.3 d
^{16}O	$^{16}\text{O}(n,x)^{11}\text{C}$	5	^{11}C	20.4 m
^{16}O	$^{16}\text{O}(n,x)^{13}\text{N}$	9	^{13}N	1.18 m
^{16}O	$^{16}\text{O}(n,x)^{15}\text{O}$	40	^{15}O	2.04 m
Spallation processes with high energy neutrons ($E_n > 20$ MeV) in Nitrogen (^{14}N)				
Target	Reaction	Cross section (mb)	Nuclide yielded	Half-life
^{14}N	$^{14}\text{N}(n,x)^3\text{H}$	30	^3H	12.3 y
^{14}N	$^{14}\text{N}(n,x)^7\text{Be}$	10	^7Be	53.3 d
^{14}N	$^{14}\text{N}(n,x)^{11}\text{C}$	10	^{11}C	20.4 m
^{14}N	$^{14}\text{N}(n,x)^{13}\text{N}$	10	^{13}N	1.18 m

Metallic components activation (accelerator parts, beam line elements,...)

Spallation, (n,x) , and neutron capture, (n,γ) , processes

Long-lives isotopes yielded directly with protons





Many equipment and elements of the facility with natural Cu

Nuclide	Half-life	Reaction	Cross section (barn)
^{137}Cs	2.06 year	$^{137}\text{Cs}(n,\gamma)^{138}\text{Cs}$	29
^{60}Co	5.3 year	$^{60}\text{Co}(n,\gamma)^{61}\text{Co}$	37
^{59}Fe	44 days	$^{59}\text{Fe}(n,\gamma)^{60}\text{Fe}$	1.15
^{65}Zn	244 days	$^{65}\text{Zn}(n,\gamma)^{66}\text{Zn}$	0.78
^{54}Mn	312 days	$^{54}\text{Mn}(n,2n)^{53}\text{Mn}$	0.91
		$^{54}\text{Fe}(n,p)^{54}\text{Mn}$	0.59
^{108}Ag	127 year	$^{107}\text{Ag}(n,\gamma)^{108}\text{Ag}$	36
^{109}Ag	249 days	$^{109}\text{Ag}(n,\gamma)^{110}\text{Ag}$	91
^{120}Sn	129 days	$^{120}\text{Sn}(n,\gamma)^{121}\text{Sn}$	0.15
^{120}Sn	9 days	$^{120}\text{Sn}(n,\gamma)^{120}\text{Sn}$	0.13
^{23}Na	2.6 year	$^{23}\text{Na}(n,2n)^{22}\text{Na}$	0.017
		$^{27}\text{Al}(n,x)^{23}\text{Na}$	0.010

Isotopes	Half-life	Parent	Reaction	Reaction Product	Half-life
^{60}Co	5.3 years		(n,γ)	^{64}Cu	12.7 hours
^{57}Co	271 days	^{63}Cu	(n,α)	^{60}Co	5.3 years
^{58}Co	70 days	69.17%	$(n,2n)$	^{64}Cu	12.7 hours
^{54}Mn	312 days		(n,p)	^{65}Ni	2.5 hours
^{65}Zn	244 days	^{65}Cu	(p,n)	^{65}Zn	244 days
^{22}Na	2.6 years	30.83%			



Air activation in CPTC

MC methods



Soil activation in CPTC

Results: MC methods



No activation with soil slabs:



> 75 cm (cyclotrons)

> 50 cm (synchrotrons)

Fiberglass recommended



Impact of new developments (Evolution of delivery methods)

PT.1 → Passive methods → Scattering → High production of secondary neutrons



PT.2 → Active methods → Pencil Beam Scanning (PBS) → IMPT (*Intensity modulated proton therapy*)

Current Basic Workload



PT.3 → In-development methods

- Flash-therapy → Disruptive
 - Mini-beams
 - PMAT → Energetic arc therapy → Relative
 - Blended modes (active+passive)
- Where we are going

Yap et. al., 2021, *Frontiers in Oncology*, 11, 780025

Impact of new delivery techniques on RP


New delivery modes: Special consideration (IAEA Tec-Doc 1891, 2020)

PMAT (Experimental)

Proton Monoenergetic Arc Therapy (Dr. Carabe- Fernandez)

Dosimetric plans PMAT/IMPT

Set-up for experimental measurements, H*(10)



Carabe-Fernández et al., 2020, *Physics Medical and Biology*, 65:165002



Bertolet and Carabe-Fernández, 2020, *Physics Medical and Biology*, 65:165006

Which delivery method yields less secondary neutron dose, PMAT or IMPT?

6 Gy

IMPT
SOBP
141.7 – 89.5 MeV


PMAT
Monoenergetic
117.5 MeV



García-Fernández et al., 2021, IRPA15

Radiation in action

by Dr Carabe-Fernández



Case 2: Dose rate 25 Gy/s, transmission method, 230 MeV


IDR = 18 $\mu\text{Sv/h}$ > 10 $\mu\text{Sv/h}$ in some areas

IDR different in different countries


Dead time of radiation monitors

(5-10 microsecond)

Underestimations



Garcia-Fernandez et. al., 2022, In Development



PHITS, 2021, tutorial

Another way to make more realistic assumptions







Experimental measurements to better assess the impact of new delivery techniques in development

Carry-out of experimental measurements



Another complementary way to make more realistic assumptions in workload

Carry-out of experimental measurements



Another complementary way to make more realistic assumptions in workload





Extended-range rem-meters

Selecting the right device for each application: Characterizing response of devices

To carry out experimental measurements inside treatment rooms is necessary extended-range rem-meters (PNF with some new delivery methods)

Outdoor is possible using conventional devices


actives




Verify assumptions and anticipate the impact of future developments

Developments could dramatically mitigate the effects of neutrons in proton therapy centers

Reducing
neutronic
burden
(PBS)




Kaderka et al., 2012, Phys. Med. Biol. 57 5959



Hålg et al., 2014, Phys. Med. Biol. 59 2457

Using
concretes
with low
content in
impurities
(Eu for
example)



García-Fernández et al., 2021, IRPA15

Assumptions should be conservative but realistic, and based on updated information





Figure 2. Lay-out of the facility
A...G are the measurement locations.
T indicates positions of TLD detectors in the building

Measurement Location	Simulation $\mu\text{Sv}/\text{year}$	Simulation $\mu\text{Sv}/\text{nAh}$	Measured Dose/nAh	Simulation/Measurement
A	110	0,0229	0,000768	30
B	2	0,0004	0,000024	17
C	5	0,0010	0,00012	9
D	6	0,0013	0,00016	7
E	12	0,0025	0,00079	32
F	7	0,0015	0,00096	15
G	30	0,0063	0,00079	8
H	50	0,0104	0,0003	35

Table 1: comparison of MC-predicted and actual yearly dose levels at the locations shown in Figure 2.

Bolt et al., PTC58-0127, PTCOG 2020 online

7 - 35



Herault et al., Radiation Protection in PT in 1er Int. course on PT, Institute Curie, Paris, 2018



The Ten “Commandments” of RP in Compact Proton Therapy Centers (CPTC)

1. Select a suitable site and location for facility
2. Design barriers and shielding against neutron and gamma radiation
3. Use Monte Carlo simulations and check with analytical methods (or if you prefer, the opposite)
4. Choose appropriate materials in barriers
5. Review the impact of radiation on environment
6. Anticipate changes in assumptions and future developments
7. Place the right radiation monitor in the right place of the facility
8. Pick suitable personal dosimeters
9. Assume uncertainties but collect as much information as possible (soil, cement, concrete,...)
10. Carry out experimental measurements

Contributions to the commissioning of operational radiation protection in CPTC

Summary

1. The design of some **aspects of operational radiation protection was developed from 2018 until now**, within the research project Contributions to operational radiation protection and neutron dosimetry in compact proton therapy centers.
2. Currently, radiological protection in PTCs is carried out with **very conservative assumptions and high safety margins**, however, developments in proton therapy could have a huge impact in the operational radiation protection. Some developments could strongly change inputs in the workload and probably will rise the requirements.
3. The aim of this work was to present a commissioning process of the operational radiation protection of Compact Proton Centers, **summarized in ten main recommendations**, achieved in the activities mentioned above, **and lined up with requirements of Nuclear Authority (CSN)**. The goal of this process is to guarantee the compliance of dose limits for clinical and technical staff, and general public.
4. **Nuclear data are essential** for the comprehensive development of a research of this nature

The development of more efficient radiation protection measures could, significantly, optimize the thickness of the barriers, lowering the cost and size required to implement a proton therapy center, and in this way, the access to proton therapy could be easier for more countries and patients.

Thanks all the team

**Hybrid Meeting (virtual & in-person) on
“Nuclear Databases for Nuclear Reactor Applications
within the Spanish Nuclear Sector”**

September 20 (Tuesday), 2022. 09:00-13:00h

Acknowledgements

Nuria García Arranz (UPM)
Oscar Cabellos (UPM)

Santiago Sánchez Cervera (CSN)
Arturo Pérez Mulas (CSN)
Marisa Tormo (CSN)

Nuclear Safety Chair Federico Goded, CSN-UPM
Luis Núñez

Alejandro Mazal (QuirónSalud)
Juan Castro (QuirónSalud)
Juan Antonio Vera (QuirónSalud)

Carlos Guerrero Sánchez (CNA)
Begoña Fernández Martínez (CNA)
Rafael García Tenorio (CNA)

Josep M. Martí (CUN)
Verónica Martín (CUN)

Erick Diffenderfer (UPenn)

Eduardo Fuentes (Bioterra)
Marisa Ogando (Bioterra)

Ricardo Otero (IBA-Spain)



Thank you for your attention

Muchas gracias

Gonzalo García
Assistant professor and researcher
Universidad Politécnica de Madrid (UPM)
gf.garcia@upm.es